Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease.

The cause of neurodegeneration in Parkinson's disease (PD) remains unknown. However, isoquinoline derivatives structurally related to the selective dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite, 1-methyl-4-phenylpyridinim (MPP+), have emerged as candidate endogenous neurotoxins causing nigral cell death in Parkinson's disease. Isoquinoline derivatives are widely distributed in the environment, being present in many plants and foodstuffs, and readily cross the blood-brain barrier. These compounds occur naturally in human brain where they are synthesized by non-enzymatic condensation of biogenic amines (e.g. catecholamines and phenylethylamine) with aldehydes, and are metabolized by cytochrome P450s and N-methyltransferases. In addition, isoquinoline derivatives are oxidized by monoamine oxidases to produce isoquinolinium cations with the concomitant generation of reactive oxygen species. Neutral and quaternary isoquinoline derivatives accumulate in dopaminergic nerve terminals via the dopamine re-uptake system, for which they have moderate to poor affinity as substrates. Several isoquinoline derivatives are selective and more potent inhibitors of NADH ubiquinone reductase (complex I) and alpha-ketoglutarate dehydrogenase activity in mitochondrial fragments than MPP+, and lipophilicity appears to be important for complex I inhibition by isoquinoline derivatives. However, compared with MPP+, isoquinoline derivatives are selective but less potent inhibitors of NADH-linked respiration in intact mitochondria, and this appears to be a consequence of their rate-limiting ability to cross mitochondrial membranes. Although both active and passive processes are involved in the accumulation of isoquinoline derivatives in mitochondria, inhibition of respiration is determined by steric rather than electrostatic properties. Compared with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or MPP+, isoquinoline derivatives show selective but relatively weak toxicity to dopamine-containing cells in culture and following systemic or intracerebral administration to experimental animals, which appears to be a consequence of poor sequestration of isoquinoline derivatives by mitochondria and by dopamine-containing neurones. In conclusion, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-like cytotoxic characteristics of isoquinoline derivatives and the endogenous/environmental presence of these compounds make it conceivable that high concentrations of and/or prolonged exposure to isoquinoline derivatives might cause neurodegeneration and Parkinson's disease in humans.

[1]  S. Ohta,et al.  TETRAHYDROISOQUINOLINE AND 1-METHYL-TETRAHYDROISOQUINOLINE ARE PRESENT IN THE HUMAN BRAIN: RELATION TO PARKINSON’S DISEASE , 1987 .

[2]  I. Kanazawa,et al.  Debrisoquine hydroxylase and Parkinson's disease. , 1993, Advances in neurology.

[3]  R. Waring,et al.  Xenobiotic metabolism in Parkinson's disease , 1989, Neurology.

[4]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[5]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[6]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[7]  M. Naoi,et al.  An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.

[8]  C. Marsden,et al.  Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. , 1996, Biochemical pharmacology.

[9]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[10]  Y. Mizuno,et al.  Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain , 1992, Journal of the Neurological Sciences.

[11]  M. Naoi,et al.  Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.

[12]  J. Langston,et al.  MPTP and parkinson's disease , 1985, Trends in Neurosciences.

[13]  T. Niwa,et al.  Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.

[14]  C. Marsden,et al.  Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Neuroreport.

[15]  S. Ohta,et al.  Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. , 1986, Biochemical and biophysical research communications.

[16]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[17]  S. Ohta,et al.  Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to Parkinson's disease. , 1988, Life sciences.

[18]  P. Carrupt,et al.  Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. , 1995, Biochemical pharmacology.

[19]  C. Marsden,et al.  Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1996, Neuroscience Letters.

[20]  H. Rommelspacher,et al.  Tetrahydroisoquinolines and beta-carbolines: putative natural substances in plants and mammals. , 1985, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[21]  S. Ohta,et al.  Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate , 1996, Neuroscience Letters.

[22]  R. Ramsay,et al.  Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.

[23]  T. Origitano,et al.  Rat brain salsolinol and blood-brain barrier , 1981, Brain Research.

[24]  C. Olanow,et al.  Neurodegeneration and Neuroprotection in Parkinson's Disease , 1996 .

[25]  T. Nagatsu Isoquinoline neurotoxins in the brain and Parkinson's disease , 1997, Neuroscience Research.

[26]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[27]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Naoi,et al.  Oxidation of N‐Methyl‐1,2,3,4‐Tetrahydroisoquinoline into the N‐Methyl‐Isoquinolinium Ion by Monoamine Oxidase , 1989, Journal of neurochemistry.

[29]  R. Ramsay,et al.  Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.

[30]  Y. Mizuno,et al.  Effect of Dopamine, Dimethoxyphenylethylamine, Papaverine, and Related Compounds on Mitochondrial Respiration and Complex I Activity , 1996, Journal of neurochemistry.

[31]  Zhenxin Zhang,et al.  Worldwide occurrence of Parkinson's disease , 1993 .

[32]  M. Naoi,et al.  A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. , 1989, Biochemical and biophysical research communications.

[33]  N. Hattori,et al.  An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease , 1994 .

[34]  C. Marsden,et al.  Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.

[35]  T. Nagatsu,et al.  Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. , 1993, Advances in neurology.

[36]  G. Sobue,et al.  A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigro-striatal system of the human brain , 1997, Neuroscience Letters.

[37]  T. Niwa,et al.  Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. , 1989, Journal of chromatography.

[38]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[39]  J. Langston,et al.  Neurotoxins, parkinsonism and Parkinson's disease. , 1987, Pharmacology & therapeutics.

[40]  K. Kikuchi,et al.  Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[41]  L. Forno Pathology of Parkinson's disease , 1981 .

[42]  Y. Mizuno,et al.  Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain , 1988, Journal of the Neurological Sciences.

[43]  O. Phillipson,et al.  1, 2, 3, 4‐Tetrahydro‐2‐Methyl‐4, 6, 7‐Isoquinolinetriol Depletes Catecholamines in Rat Brain , 1993, Journal of neurochemistry.

[44]  S. Ohta,et al.  Novel Endogenous 1,2,3,4‐Tetrahydroisoquinoline Derivatives: Uptake by Dopamine Transporter and Activity to Induce Parkinsonism , 1998, Journal of neurochemistry.

[45]  R. Ramsay,et al.  Studies on the Characterization of the Inhibitory Mechanism of 4′‐Alkylated 1‐Methyl‐4‐Phenylpyridinium and Phenylpyridine Analogues in Mitochondria and Electron Transport Particles , 1994, Journal of neurochemistry.

[46]  M. Naoi,et al.  N-methyl(R)salsolinol produces hydroxyl radicals: involvement to neurotoxicity. , 1995, Free radical biology & medicine.

[47]  A. Szczudlik,et al.  Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology , 1997, Biological Psychiatry.

[48]  R. Ross Drug-Induced Parkinsonism and Other Movement Disorders , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[49]  T. Niwa,et al.  Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. , 1988, Journal of chromatography.

[50]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[51]  J. Cashaw Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography. , 1993, Journal of chromatography.

[52]  G. Cohen,et al.  Tetrahydroisoquinoline alkaloids: uptake by rat brain homogenates and inhibition of catecholamine uptake. , 1971, The Journal of pharmacology and experimental therapeutics.

[53]  T. Niwa,et al.  Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. , 1987, Biochemical and biophysical research communications.

[54]  J. Barker,et al.  Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum , 1989, Brain Research.

[55]  C. Marsden,et al.  New insights into the cause of Parkinson's disease , 1992, Neurology.

[56]  J. Cooper,et al.  Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.

[57]  D. D. Di Monte,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. , 1986, Biochemical and biophysical research communications.

[58]  S. Ohta,et al.  Cytochrome P450 isozymes catalyzing 4‐hydroxylation of parkinsonism‐related compound 1,2,3,4‐tetrahydroisoquinoline in rat liver microsomes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  H. Rommelspacher,et al.  β-Carbolines and Tetrahydroisoquinolines: Detection and Function in Mammals , 1991, Planta medica.

[60]  C. Hoppel,et al.  Dopaminergic Neurotoxicity In Vivo and Inhibition of Mitochondrial Respiration In Vitro by Possible Endogenous Pyridinium‐Like Substances , 1991, Journal of neurochemistry.

[61]  S. Ohta,et al.  1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.

[62]  H. Nakamura,et al.  Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XVI. Characteristics of the membrane-bound dehydrogenase in Candida utilis and Saccharomyces cerevisiae. , 1970, Archives of biochemistry and biophysics.

[63]  J. Smyth,et al.  Progress in Clinical and Biological Research , 1979 .

[64]  G. Román,et al.  Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.

[65]  C. Marsden,et al.  Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1996, Biochemical pharmacology.

[66]  M. Naoi,et al.  Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection. , 1990, Journal of chromatography.

[67]  C. Marsden,et al.  Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease , 1997, The Lancet.

[68]  K. Jones,et al.  Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice , 1988, Neuroscience Letters.

[69]  Y. Mizuno,et al.  Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.

[70]  D. Greenblatt,et al.  Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP. , 1987, Biochemical and biophysical research communications.

[71]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[72]  M. Naoi,et al.  N‐Methylation of Dopamine‐Derived 6,7‐Dihydroxy‐1,2,3,4‐Tetrahydroisoquinoline, (R)‐Salsolinol, in Rat Brains: In Vivo Microdialysis Study , 1992, Journal of neurochemistry.

[73]  A. Zuddas,et al.  MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra , 1989, Brain Research.

[74]  D. Acosta,et al.  Changes in glutathione and cellular energy as potential mechanisms of papaverine-induced hepatotoxicity in vitro. , 1991, Toxicology and applied pharmacology.

[75]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[76]  A H Schapira,et al.  Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. , 1997, Brain research.

[77]  C. Olanow,et al.  Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders , 1996 .

[78]  M. Naoi,et al.  Dopamine‐Derived 1‐Methyl‐6,7‐Dihydroxyisoquinolines as Hydroxyl Radical Promoters and Scavengers in the Rat Brain: In Vivo and In Vitro Studies , 1995, Journal of neurochemistry.

[79]  Y. Mizuno,et al.  Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture , 1997, Brain Research.

[80]  S. Markey,et al.  Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease , 1992, Brain Research.

[81]  R. Deitrich,et al.  Biogenic amine-aldehyde condensation products: tetrahydroisoquinolines and tryptolines (beta-carbolines). , 1980, Annual review of pharmacology and toxicology.

[82]  A. Harvey Natural and synthetic neurotoxins , 1993 .

[83]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[84]  K. Suzuki,et al.  Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. , 1989, Biochemical and biophysical research communications.